Magnite (NASDAQ:MGNI) Shares Gap Up - Here's What Happened

Magnite (NASDAQ:MGNI) Shares Gap Up - Here's What Happened

Magnite (NASDAQ:MGNI) Shares Gap Up - Time to Buy?

Uniqure Dives 35% On Another Shock For Its Gene Therapy

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease.

UniQure’s Huntington’s therapy fails to significantly slow disease progression, shares plunge

Sept 29 (Reuters) - UniQure said its gene therapy for Huntington's ​disease fell short ‌of statistical significance on the main goal of slowing disease progression ‌in ​a four-year ⁠analysis, sending ⁠its U.S.-listed shares plummeting 55% in premarket ...

UniQure tumbles with latest data for Huntington’s gene therapy

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec ...

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed…

UniQure's gene therapy continues to slow Huntington's progression after four years

UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year ago.